Advarra’s Post

Curious about how Origify can transform pharmaceutical authentication 🏥? Explore our approach in the latest pharmind article by ECV - Editio Cantor Verlag GmbH titled "Digitaler Fingerabdruck: Authentifizierung für Medizin- und Pharmaprodukte“. Discover more by following this link 🔗: https://lnkd.in/ejdzrWkU, and don't hesitate to share your thoughts in the comments section below 📝.   #Bosch #Origify #ProductAuthentication #PharmaceuticalAuthentication #DigitalFingerprint #Pharmind  

With so many options to choose from, Peter M. Wahl, MLA, MS, ScD sits down with Pharmaceutical Executive for a deeper dive into protocol-driven registries, key factors to consider when choosing the registry that best suits your needs, and regulatory requirements. Learn more about the use of registries as sources of regulatory-grade #RWE -->> Click to view the video!

A great interview where our expert on registries Peter M. Wahl, MLA, MS, ScD talks about how this strategic investment can be a robust source for real world evidence (#RWE) able to serve multiple and evolving evidence needs across the drug development cycle. Go take a look and let me know if you would like to discuss with us your specific needs.

More than half of all recent #warningletters issued by the FDA include citations for absent or incomplete #riskassessments. In this new Pharmaceutical Online article, Virginia Andreotti-Jones, Danica Brown, and Heather Hafer-DeMilto of ValSource Inc. examine what regulators are looking for and provide four helpful case studies. https://lnkd.in/eMTZ7MY3 #regulatorycompliance #qualitymanagement #riskmanagement

Announcing the introduction of HealthVerity taXOnomy, integrating closed (X) and open (O) claims for the most expansive, exacting, and efficient approach to pharmaceutical research and sophisticated commercial strategies. https://hubs.ly/Q02NxVKQ0

The @U.S. Department of Health and Human Services’ (HHS) will conduct a study on how the domestic pharmaceutical supply chain changed during COVID. In April 2024, HHS published a white paper highlighting the critical role manufacturing plays in building the domestic drug supply. The document proposed several actions to nurture resilience, including the aforementioned study and a Manufacturer Resiliency Assessment Program (MRAP). Learn more: https://lnkd.in/duJ_zm_G #genericdrugs #supplychain

Stay on top of latest ICH developments ny reading this paper.

Check out our latest publication on ICH Q2(R2)! The US Pharmacopeia Analytical Procedure Lifecycle Joint Subcommittee explores the latest advancements in ICH Q2(R2) guidelines on validation of analytical procedures and their implications for industry. We also identified areas that would benefit from additional guidance and compare how the latest ICH Q14/Q2(R2) guidelines align with USP approach. Be sure to have a read at this critical review of #ICH Q2(R2) in European Pharmaceutical Review (EPR)! And stay tuned... a more detailed paper is coming up. 💡 Paper: https://lnkd.in/dBM6Kd5i USP is 𝐑𝐞𝐜𝐫𝐮𝐢𝐭𝐢𝐧𝐠 𝐄𝐱𝐩𝐞𝐫𝐭 𝐕𝐨𝐥𝐮𝐧𝐭𝐞𝐞𝐫𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 – 𝟐𝟎𝟑𝟎 𝐂𝐲𝐜𝐥𝐞: https://lnkd.in/dCeHNSve #Assay #Bioassay #Validation #Lifecycle #ProcedureLifecycle #uspharmacopeia

A few days ago we had gone through how HPLC is of impact in pharmaceutical industry. This article here highlights advancement in analytical instrumentation. This is a must read 💡

Companies now have a way to increase the visibility of the overall medical claims market versus being limited to seeing only 40-50%. Increasing the visibility of the market by 20-30% will fill in a number of data gaps that exist. This will now allow companies to see more of the market and be more precise in developing their overall marketing strategies and in the end improve outcomes for patients. This is a great day for the industry and for patients.